We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -15.00 | -0.91% | 1,636.00 | 1,638.00 | 1,639.00 | 1,661.50 | 1,635.50 | 1,656.50 | 4,329,161 | 16:35:12 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.69 | 67.46B |
From Apr 2019 to Apr 2024
By Tapan Panchal
LONDON--GlaxoSmithKline PLC (GSK.LN) and Theravance Inc. (THRX) have submitted a supplemental new drug application to the U.S. Food and Drug Administration for a drug used for treatment of asthma in patients aged 12 years and older.
The British pharmaceutical company said Monday that the application is for a fixed-dose combination of fluticasone furoate and vilanterol as a once-daily treatment for asthma. The application has been filed under the brand name of Breo Ellipta and is seeking approval for two dose regimens, 100/25 micrograms and 200/25 micrograms.
GSK said the filing is based upon data from a comprehensive clinical development program.
Shares of GSK at 1111 GMT are trading 0.6% lower at 1563 pence.
Write to Tapan Panchal at tapan.panchal@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
